Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.

Merlino G, Fiascarelli A, Bigioni M, Bressan A, Carrisi C, Bellarosa D, Salerno M, Bugianesi R, Manno R, Bernadó Morales C, Arribas J, Dusek RL, Ackroyd JE, Pham PH, Awdew R, Aud D, Trang M, Lynch CM, Terrett J, Wilson KE, Rohlff C, Manzini S, Pellacani A, Binaschi M.

Mol Cancer Ther. 2019 Sep;18(9):1533-1543. doi: 10.1158/1535-7163.MCT-18-0624. Epub 2019 Jun 21.

PMID:
31227646
2.

Targeting CD157 in AML using a novel, Fc-engineered antibody construct.

Krupka C, Lichtenegger FS, Köhnke T, Bögeholz J, Bücklein V, Roiss M, Altmann T, Do TU, Dusek R, Wilson K, Bisht A, Terrett J, Aud D, Pombo-Villar E, Rohlff C, Hiddemann W, Subklewe M.

Oncotarget. 2017 May 30;8(22):35707-35717. doi: 10.18632/oncotarget.16060.

3.

A role for mitogen kinase kinase 3 in pulmonary inflammation validated from a proteomic approach.

Holand T, Riffo-Vasquez Y, Spina D, O'Connor B, Woisin F, Sand C, Marber M, Bacon KB, Rohlff C, Page CP.

Pulm Pharmacol Ther. 2014 Apr;27(2):156-63. doi: 10.1016/j.pupt.2014.01.006. Epub 2014 Jan 27.

PMID:
24480516
4.

New approaches towards integrated proteomic databases and depositories.

Rohlff C.

Expert Rev Proteomics. 2004 Oct;1(3):267-74.

PMID:
15966823
5.

Proteomic approaches in drug discovery and development.

Soares HD, Williams SA, Snyder PJ, Gao F, Stiger T, Rohlff C, Herath A, Sunderland T, Putnam K, White WF.

Int Rev Neurobiol. 2004;61:97-126. Review. No abstract available.

PMID:
15482813
6.

Modern proteomic strategies in the study of complex neuropsychiatric disorders.

Rohlff C, Hollis K.

Biol Psychiatry. 2003 May 15;53(10):847-53. Review. Erratum in: Biol Psychiatry. 2003 Jun 15;53(12):1148.

PMID:
12742671
7.

Proteomic approaches to central nervous system disorders.

Rohlff C, Southan C.

Curr Opin Mol Ther. 2002 Jun;4(3):251-8. Review.

PMID:
12139311
8.

Hyaluronidase gene profiling and role of hyal-1 overexpression in an orthotopic model of prostate cancer.

Patel S, Turner PR, Stubberfield C, Barry E, Rohlff CR, Stamps A, McKenzie E, Young K, Tyson K, Terrett J, Box G, Eccles S, Page MJ.

Int J Cancer. 2002 Feb 1;97(4):416-24. Erratum in: Int J Cancer 2002 Apr 20;98(6):957.

9.

Proteomics in neuropsychiatric disorders.

Rohlff C.

Int J Neuropsychopharmacol. 2001 Mar;4(1):93-102. doi: 10.1017/S1461145701002267. Review.

PMID:
11343634
10.

Proteomics in molecular medicine: applications in central nervous systems disorders.

Rohlff C.

Electrophoresis. 2000 Apr;21(6):1227-34. Review.

PMID:
10786895
11.

Proteomics: a major new technology for the drug discovery process.

Page MJ, Amess B, Rohlff C, Stubberfield C, Parekh R.

Drug Discov Today. 1999 Feb;4(2):55-62.

PMID:
10234157
12.

A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2.

Rohlff C, Watson SA, Morris TM, Skelton L, Jackman AL, Page MJ.

Cancer Res. 1999 Mar 15;59(6):1268-72.

13.

Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1).

Rohlff C, Blagosklonny MV, Kyle E, Kesari A, Kim IY, Zelner DJ, Hakim F, Trepel J, Bergan RC.

Prostate. 1998 Sep 15;37(1):51-9.

PMID:
9721069
14.
15.

Post-translational modification of proteins and the discovery of new medicine.

Parekh RB, Rohlff C.

Curr Opin Biotechnol. 1997 Dec;8(6):718-23. Review.

PMID:
9425663
16.

Modulation of transcription factor Sp1 by cAMP-dependent protein kinase.

Rohlff C, Ahmad S, Borellini F, Lei J, Glazer RI.

J Biol Chem. 1997 Aug 22;272(34):21137-41.

17.

Regulation of multidrug resistance through the cAMP and EGF signalling pathways.

Rohlff C, Glazer RI.

Cell Signal. 1995 Jul;7(5):431-43. Review. Erratum in: Cell Signal 1996 Feb;8(2):151.

PMID:
8562304
18.
19.

Transcriptional regulation of multidrug resistance in breast cancer.

Glazer RI, Rohlff C.

Breast Cancer Res Treat. 1994;31(2-3):263-71. Review.

PMID:
7881104
20.

8-chloroadenosine 3',5'-monophosphate as a novel modulator of multidrug-resistance.

Yokozaki H, Budillon A, Clair T, Kelley K, Cowan K, Rohlff C, Glazer R, Chochung Y.

Int J Oncol. 1993 Sep;3(3):423-30.

PMID:
21573381

Supplemental Content

Loading ...
Support Center